Beyond Death: Unmasking the Intricacies of Apoptosis Escape.
Journal
Molecular diagnosis & therapy
ISSN: 1179-2000
Titre abrégé: Mol Diagn Ther
Pays: New Zealand
ID NLM: 101264260
Informations de publication
Date de publication:
18 Jun 2024
18 Jun 2024
Historique:
accepted:
14
05
2024
medline:
19
6
2024
pubmed:
19
6
2024
entrez:
18
6
2024
Statut:
aheadofprint
Résumé
Apoptosis, or programmed cell death, maintains tissue homeostasis by eliminating damaged or unnecessary cells. However, cells can evade this process, contributing to conditions such as cancer. Escape mechanisms include anoikis, mitochondrial DNA depletion, cellular FLICE inhibitory protein (c-FLIP), endosomal sorting complexes required for transport (ESCRT), mitotic slippage, anastasis, and blebbishield formation. Anoikis, triggered by cell detachment from the extracellular matrix, is pivotal in cancer research due to its role in cellular survival and metastasis. Mitochondrial DNA depletion, associated with cellular dysfunction and diseases such as breast and prostate cancer, links to apoptosis resistance. The c-FLIP protein family, notably CFLAR, regulates cell death processes as a truncated caspase-8 form. The ESCRT complex aids apoptosis evasion by repairing intracellular damage through increased Ca2+ levels. Antimitotic agents induce mitotic arrest in cancer treatment but can lead to mitotic slippage and tetraploid cell formation. Anastasis allows cells to resist apoptosis induced by various triggers. Blebbishield formation suppresses apoptosis indirectly in cancer stem cells by transforming apoptotic cells into blebbishields. In conclusion, the future of apoptosis research offers exciting possibilities for innovative therapeutic approaches, enhanced diagnostic tools, and a deeper understanding of the complex biological processes that govern cell fate. Collaborative efforts across disciplines, including molecular biology, genetics, immunology, and bioinformatics, will be essential to realize these prospects and improve patient outcomes in diverse disease contexts.
Identifiants
pubmed: 38890247
doi: 10.1007/s40291-024-00718-w
pii: 10.1007/s40291-024-00718-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Chiarugi P, Giannoni E. Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol. 2008;76(11):1352–64.
pubmed: 18708031
doi: 10.1016/j.bcp.2008.07.023
Grossmann J. Molecular mechanisms of “detachment-induced apoptosis—Anoikis.” Apoptosis. 2002;7:247–60.
pubmed: 11997669
doi: 10.1023/A:1015312119693
Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol. 2001;13(5):555–62.
pubmed: 11544023
doi: 10.1016/S0955-0674(00)00251-9
Tsai J-Y, Tsai S-H, Wu C-C. The chemopreventive isothiocyanate sulforaphane reduces anoikis resistance and anchorage-independent growth in non-small cell human lung cancer cells. Toxicol Appl Pharmacol. 2019;362:116–24.
pubmed: 30365975
doi: 10.1016/j.taap.2018.10.020
Ye G, et al. Nuclear MYH9-induced CTNNB1 transcription, targeted by staurosporin, promotes gastric cancer cell anoikis resistance and metastasis. Theranostics. 2020;10(17):7545.
pubmed: 32685004
pmcid: 7359096
doi: 10.7150/thno.46001
Zhang X, et al. A miR-124/ITGA3 axis contributes to colorectal cancer metastasis by regulating anoikis susceptibility. Biochem Biophys Res Commun. 2018;501(3):758–64.
pubmed: 29758195
doi: 10.1016/j.bbrc.2018.05.062
Sousa B et al. P-cadherin induces anoikis-resistance of matrix-detached breast cancer cells by promoting pentose phosphate pathway and decreasing oxidative stress. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease. 2020;1866(12): 165964.
Yu Y, et al. CircCEMIP promotes anoikis-resistance by enhancing protective autophagy in prostate cancer cells. J Exp Clin Cancer Res. 2022;41(1):1–17.
doi: 10.1186/s13046-022-02381-7
Bunek J, Kamarajan P, Kapila YL. Anoikis mediators in oral squamous cell carcinoma. Oral Dis. 2011;17(4):355–61.
pubmed: 21114588
doi: 10.1111/j.1601-0825.2010.01763.x
Jalilzadeh N et al. Understanding and targeting anoikis in metastasis for cancer therapies. Cell Biol Int. 2022.
de Sousa Mesquita AP, et al. Acquisition of anoikis resistance promotes alterations in the Ras/ERK and PI3K/Akt signaling pathways and matrix remodeling in endothelial cells. Apoptosis. 2017;22:1116–37.
pubmed: 28653224
doi: 10.1007/s10495-017-1392-0
Tafolla E, et al. JNK1 and JNK2 oppositely regulate p53 in signaling linked to apoptosis triggered by an altered fibronectin matrix: JNK links FAK and p53. J Biol Chem. 2005;280(20):19992–9.
pubmed: 15778501
doi: 10.1074/jbc.M500331200
Sanchez-Ruderisch H, et al. Galectin-1 sensitizes carcinoma cells to anoikis via the fibronectin receptor α5β1-integrin. Cell Death Differ. 2011;18(5):806–16.
pubmed: 21113146
doi: 10.1038/cdd.2010.148
Paoli P, Giannoni E, and Chiarugi P. Anoikis molecular pathways and its role in cancer progression. Biochimica et Biophysica Acta (BBA)-Mol Cell Res. 2013;1833(12):3481–3498.
Adeshakin FO, et al. Mechanisms for modulating anoikis resistance in cancer and the relevance of metabolic reprogramming. Front Oncol. 2021;11: 626577.
pubmed: 33854965
pmcid: 8039382
doi: 10.3389/fonc.2021.626577
Cai Q, Yan L, Xu Y. Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells. Oncogene. 2015;34(25):3315–24.
pubmed: 25132267
doi: 10.1038/onc.2014.264
Rytömaa M, Martins LM, Downward J. Involvement of FADD and caspase-8 signalling in detachment-induced apoptosis. Curr Biol. 1999;9(18):1043–6.
pubmed: 10508619
doi: 10.1016/S0960-9822(99)80454-0
Bachelder RE, et al. The cleavage of Akt/protein kinase B by death receptor signaling is an important event in detachment-induced apoptosis. J Biol Chem. 2001;276(37):34702–7.
pubmed: 11463786
doi: 10.1074/jbc.M102806200
Yoon SJ, DeNicola GM. IL1RAP pulls a double shift in the cysteine factory. Cancer Discov. 2021;11(11):2679–81.
pubmed: 34725089
doi: 10.1158/2159-8290.CD-21-1053
Hilmarsdottir B, et al. Inhibition of PTP1B disrupts cell–cell adhesion and induces anoikis in breast epithelial cells. Cell Death Dis. 2017;8(5):e2769–e2769.
pubmed: 28492548
pmcid: 5520702
doi: 10.1038/cddis.2017.177
Stupack DG, et al. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol. 2001;155(3):459–70.
pubmed: 11684710
pmcid: 2150834
doi: 10.1083/jcb.200106070
Varadaraj A, et al. Epigenetic regulation of GDF2 suppresses anoikis in ovarian and breast epithelia. Neoplasia. 2015;17(11):826–38.
pubmed: 26678910
pmcid: 4681890
doi: 10.1016/j.neo.2015.11.003
Yu X, et al. Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer. Cancer Sci. 2008;99(3):543–52.
pubmed: 18201274
pmcid: 11159160
doi: 10.1111/j.1349-7006.2007.00722.x
An H, et al. Salinomycin promotes anoikis and decreases the CD44+/CD24-stem-like population via inhibition of STAT3 activation in MDA-MB-231 cells. PLoS One. 2015;10(11): e0141919.
pubmed: 26528725
pmcid: 4631341
doi: 10.1371/journal.pone.0141919
Yang L, et al. Regulation of AMPK-related glycolipid metabolism imbalances redox homeostasis and inhibits anchorage independent growth in human breast cancer cells. Redox Biol. 2018;17:180–91.
pubmed: 29702405
pmcid: 6006728
doi: 10.1016/j.redox.2018.04.016
Saleem MZ et al. Brevilin A inhibits STAT3 signaling and induces ROS-dependent apoptosis, mitochondrial stress and endoplasmic reticulum stress in MCF-7 breast cancer cells. OncoTargets and Therapy, 2020;p. 435–50.
Schömel N, et al. UGCG influences glutamine metabolism of breast cancer cells. Sci Rep. 2019;9(1):15665.
pubmed: 31666638
pmcid: 6821892
doi: 10.1038/s41598-019-52169-7
Peppicelli S, et al. Anoikis resistance as a further trait of acidic-adapted melanoma cells. J Oncol. 2019. https://doi.org/10.1155/2019/8340926 .
doi: 10.1155/2019/8340926
pubmed: 31275384
pmcid: 6582804
Sawyer BT, et al. Targeting fatty acid oxidation to promote anoikis and inhibit ovarian cancer progression. Mol Cancer Res. 2020;18(7):1088–98.
pubmed: 32198139
pmcid: 7335321
doi: 10.1158/1541-7786.MCR-19-1057
Terasaki M, et al. Dietary fucoxanthin induces anoikis in colorectal adenocarcinoma by suppressing integrin signaling in a murine colorectal cancer model. J Clin Med. 2019;9(1):90.
pubmed: 31905803
pmcid: 7019251
doi: 10.3390/jcm9010090
Xu R, et al. Aspirin suppresses breast cancer metastasis to lung by targeting anoikis resistance. Carcinogenesis. 2022;43(2):104–14.
pubmed: 34958360
doi: 10.1093/carcin/bgab117
Bose M, et al. Targeting tumor-associated MUC1 overcomes anoikis-resistance in pancreatic cancer. Transl Res. 2023;253:41–56.
pubmed: 36031050
doi: 10.1016/j.trsl.2022.08.010
Zhang H-F, et al. Proteomic screens for suppressors of anoikis identify IL1RAP as a promising surface target in Ewing sarcoma. Cancer Discov. 2021;11(11):2884–903.
pubmed: 34021002
pmcid: 8563374
doi: 10.1158/2159-8290.CD-20-1690
Rötig A and Poulton J. Genetic causes of mitochondrial DNA depletion in humans. Biochimica et Biophysica Acta (BBA)-Mol Basis Dis. 2009;1792(12):1103–8.
Tseng LM, et al. Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer. Genes Chromosom Cancer. 2006;45(7):629–38.
pubmed: 16568452
doi: 10.1002/gcc.20326
Petros JA, et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci. 2005;102(3):719–24.
pubmed: 15647368
pmcid: 545582
doi: 10.1073/pnas.0408894102
Filograna R, et al. Mitochondrial DNA copy number in human disease: the more the better? FEBS Lett. 2021;595(8):976–1002.
pubmed: 33314045
doi: 10.1002/1873-3468.14021
Guha M, et al. Mitochondrial retrograde signaling induces epithelial–mesenchymal transition and generates breast cancer stem cells. Oncogene. 2014;33(45):5238–50.
pubmed: 24186204
doi: 10.1038/onc.2013.467
Li X, et al. MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features. Oncotarget. 2016;7(26):40297.
pubmed: 27248169
pmcid: 5130009
doi: 10.18632/oncotarget.9610
Cook LS, et al. Endometrial cancer and a family history of cancer. Gynecol Oncol. 2013;130(2):334–9.
pubmed: 23632205
pmcid: 4052607
doi: 10.1016/j.ygyno.2013.04.053
Ferraresi R, et al. Resistance of mtDNA-depleted cells to apoptosis. Cytometry A. 2008;73(6):528–37.
pubmed: 18302187
doi: 10.1002/cyto.a.20544
Radzak A, et al. Insights regarding mitochondrial DNA copy number alterations in human cancer. Int J Mol Med. 2022;50(2):1–18.
Van Houten B, Hunter SE, Meyer JN. Mitochondrial DNA damage induced autophagy, cell death, and disease. Front Biosci (Landmark edition). 2016;21:42.
doi: 10.2741/4375
Tuppen HA et al. Mitochondrial DNA mutations and human disease. Biochimica et Biophysica Acta (BBA)-Bioenergetics. 2010;1797(2):113–28.
Rommelaere G, et al. Hypersensitivity of mtDNA-depleted cells to staurosporine-induced apoptosis: roles of Bcl-2 downregulation and cathepsin B. Am J Physiol Cell Physiol. 2011;300(5):C1090–106.
pubmed: 21068357
doi: 10.1152/ajpcell.00037.2010
Suzuki S, et al. Constitutive activation of AKT pathway inhibits TNF-induced apoptosis in mitochondrial DNA-deficient human myelogenous leukemia ML-1a. Cancer Lett. 2008;268(1):31–7.
pubmed: 18468786
pmcid: 2562876
doi: 10.1016/j.canlet.2008.03.020
Chen H, et al. Mitochondrial DNA depletion causes decreased ROS production and resistance to apoptosis. Int J Mol Med. 2016;38(4):1039–46.
pubmed: 27499009
pmcid: 5029958
doi: 10.3892/ijmm.2016.2697
Aghajanova L, et al. Obstetrics and gynecology residency and fertility needs: national survey results. Reprod Sci. 2017;24(3):428–34.
pubmed: 27368879
doi: 10.1177/1933719116657193
Park SY, et al. Resistance of mitochondrial DNA-depleted cells against cell death: role of mitochondrial superoxide dismutase. J Biol Chem. 2004;279(9):7512–20.
pubmed: 14660625
doi: 10.1074/jbc.M307677200
Biswas G, Anandatheerthavarada H, Avadhani N. Mechanism of mitochondrial stress-induced resistance to apoptosis in mitochondrial DNA-depleted C2C12 myocytes. Cell Death Differ. 2005;12(3):266–78.
pubmed: 15650755
doi: 10.1038/sj.cdd.4401553
Biswas G, Guha M, Avadhani NG. Mitochondria-to-nucleus stress signaling in mammalian cells: nature of nuclear gene targets, transcription regulation, and induced resistance to apoptosis. Gene. 2005;354:132–9.
pubmed: 15978749
pmcid: 3800739
doi: 10.1016/j.gene.2005.03.028
Jacques C, et al. mtDNA controls expression of the death associated protein 3. Exp Cell Res. 2006;312(6):737–45.
pubmed: 16413536
doi: 10.1016/j.yexcr.2005.11.027
Dey R, Moraes CT. Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-xL in osteosarcoma cells. J Biol Chem. 2000;275(10):7087–94.
pubmed: 10702275
doi: 10.1074/jbc.275.10.7087
Smiraglia D, et al. A novel role for mitochondria in regulating epigenetic modifications in the nucleus. Cancer Biol Ther. 2008;7(8):1182–90.
pubmed: 18458531
doi: 10.4161/cbt.7.8.6215
Herbert M, Turnbull D. Progress in mitochondrial replacement therapies. Nat Rev Mol Cell Biol. 2018;19(2):71–2.
pubmed: 29358685
doi: 10.1038/nrm.2018.3
Apostolova N, Victor VM. Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications. Antioxid Redox Signal. 2015;22(8):686–729.
pubmed: 25546574
pmcid: 4350006
doi: 10.1089/ars.2014.5952
Valero T. Editorial (thematic issue: mitochondrial biogenesis: pharmacological approaches). Curr Pharm Des. 2014;20(35):5507–9.
pubmed: 24606795
doi: 10.2174/138161282035140911142118
Zhao L, et al. Mesenchymal stem cell therapy targeting mitochondrial dysfunction in acute kidney injury. J Transl Med. 2019;17:1–9.
doi: 10.1186/s12967-019-1893-4
Lippi L, et al. Impact of nutraceuticals and dietary supplements on mitochondria modifications in healthy aging: a systematic review of randomized controlled trials. Aging Clin Exp Res. 2022;34(11):2659–74.
pubmed: 35920994
doi: 10.1007/s40520-022-02203-y
Dhapola R, et al. Recent advances in molecular pathways and therapeutic implications targeting mitochondrial dysfunction for Alzheimer’s disease. Mol Neurobiol. 2022;59(1):535–55.
pubmed: 34725778
doi: 10.1007/s12035-021-02612-6
Shi P, et al. The third-generation EGFR inhibitor, osimertinib, promotes c-FLIP degradation, enhancing apoptosis including TRAIL-induced apoptosis in NSCLC cells with activating EGFR mutations. Transl Oncol. 2019;12(5):705–13.
pubmed: 30856555
pmcid: 6411612
doi: 10.1016/j.tranon.2019.02.006
Shirley S, Micheau O. Targeting c-FLIP in cancer. Cancer Lett. 2013;332(2):141–50.
pubmed: 21071136
doi: 10.1016/j.canlet.2010.10.009
Thome M, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature. 1997;386(6624):517–21.
pubmed: 9087414
doi: 10.1038/386517a0
Micheau O, et al. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem. 2002;277(47):45162–71.
pubmed: 12215447
doi: 10.1074/jbc.M206882200
Chang DW, et al. c-FLIPL is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J. 2002;21(14):3704–14.
pubmed: 12110583
pmcid: 125398
doi: 10.1093/emboj/cdf356
Hughes MA, et al. Co-operative and hierarchical binding of c-FLIP and caspase-8: a unified model defines how c-FLIP isoforms differentially control cell fate. Mol Cell. 2016;61(6):834–49.
pubmed: 26990987
pmcid: 4819448
doi: 10.1016/j.molcel.2016.02.023
Chen S, et al. Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3. Can Res. 2011;71(19):6270–81.
doi: 10.1158/0008-5472.CAN-11-0838
Feoktistova M, et al. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell. 2011;43(3):449–63.
pubmed: 21737330
pmcid: 3163271
doi: 10.1016/j.molcel.2011.06.011
He M, He Y. A role for c-FLIPL in the regulation of apoptosis, autophagy, and necroptosis in T lymphocytes. Cell Death Differ. 2013;20(2):188–97.
pubmed: 23175183
doi: 10.1038/cdd.2012.148
Oberst A, et al. Catalytic activity of the caspase-8–FLIPL complex inhibits RIPK3-dependent necrosis. Nature. 2011;471(7338):363–7.
pubmed: 21368763
pmcid: 3077893
doi: 10.1038/nature09852
Lee YS, et al. Ferroptosis-inducing agents enhance TRAIL-induced apoptosis through upregulation of death receptor 5. J Cell Biochem. 2019;120(1):928–39.
pubmed: 30160785
doi: 10.1002/jcb.27456
Lee J-S, et al. FLIP-mediated autophagy regulation in cell death control. Nat Cell Biol. 2009;11(11):1355–62.
pubmed: 19838173
pmcid: 2802862
doi: 10.1038/ncb1980
Bell BD, et al. FADD and caspase-8 control the outcome of autophagic signaling in proliferating T cells. Proc Natl Acad Sci. 2008;105(43):16677–82.
pubmed: 18946037
pmcid: 2575479
doi: 10.1073/pnas.0808597105
Tomaipitinca L, et al. c-FLIP regulates autophagy by interacting with Beclin-1 and influencing its stability. Cell Death Dis. 2021;12(7):686.
pubmed: 34238932
pmcid: 8266807
doi: 10.1038/s41419-021-03957-5
Galligan L, et al. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther. 2005;4(12):2026–36.
pubmed: 16373718
doi: 10.1158/1535-7163.MCT-05-0262
Safa AR, Pollok KE. Targeting the anti-apoptotic protein c-FLIP for cancer therapy. Cancers. 2011;3(2):1639–71.
pubmed: 22348197
pmcid: 3281420
doi: 10.3390/cancers3021639
Zhang T, et al. Cross-talk between TGF-beta/SMAD and integrin signaling pathways in regulating hypertrophy of mesenchymal stem cell chondrogenesis under deferral dynamic compression. Biomaterials. 2015;38:72–85.
pubmed: 25453975
doi: 10.1016/j.biomaterials.2014.10.010
Safa AR. Roles of c-FLIP in apoptosis, necroptosis, and autophagy. J Carcinogenesis Mutagenesis. 2013.
Seo SU, et al. NOX4-mediated ROS production induces apoptotic cell death via down-regulation of c-FLIP and Mcl-1 expression in combined treatment with thioridazine and curcumin. Redox Biol. 2017;13:608–22.
pubmed: 28806703
pmcid: 5554966
doi: 10.1016/j.redox.2017.07.017
Wang W-D, et al. c-FLIP promotes drug resistance in non-small-cell lung cancer cells via upregulating FoxM1 expression. Acta Pharmacol Sin. 2022;43(11):2956–66.
pubmed: 35422085
pmcid: 9622852
doi: 10.1038/s41401-022-00905-7
Kim S, et al. KMU-191 Induces Apoptosis in human clear cell renal cell carcinoma caki cells through modulation of Bcl-xL, Mcl-1 (L), c-FLIP (L), and p53 proteins. J Cancer. 2023;14(12):2224.
pubmed: 37576393
pmcid: 10414049
doi: 10.7150/jca.85650
Park S-J, et al. Trichostatin A sensitizes human ovarian cancer cells to TRAIL-induced apoptosis by down-regulation of c-FLIPL via inhibition of EGFR pathway. Biochem Pharmacol. 2009;77(8):1328–36.
pubmed: 19426671
doi: 10.1016/j.bcp.2008.12.027
Pathil A, et al. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL. Hepatology. 2006;43(3):425–34.
pubmed: 16583461
doi: 10.1002/hep.21054
Scheffer LL, et al. Mechanism of Ca2+-triggered ESCRT assembly and regulation of cell membrane repair. Nat Commun. 2014;5(1):5646.
pubmed: 25534348
doi: 10.1038/ncomms6646
Morita E, et al. Human ESCRT and ALIX proteins interact with proteins of the midbody and function in cytokinesis. EMBO J. 2007;26(19):4215–27.
pubmed: 17853893
pmcid: 2230844
doi: 10.1038/sj.emboj.7601850
Güttinger S, Laurell E, Kutay U. Orchestrating nuclear envelope disassembly and reassembly during mitosis. Nat Rev Mol Cell Biol. 2009;10(3):178–91.
pubmed: 19234477
doi: 10.1038/nrm2641
Snyder JC, et al. Functional interplay between a virus and the ESCRT machinery in archaea. Proc Natl Acad Sci. 2013;110(26):10783–7.
pubmed: 23754419
pmcid: 3696792
doi: 10.1073/pnas.1301605110
Yoon S, et al. MLKL, the protein that mediates necroptosis, also regulates endosomal trafficking and extracellular vesicle generation. Immunity. 2017;47(1):51–65 (e7).
pubmed: 28666573
doi: 10.1016/j.immuni.2017.06.001
Ritter AT, et al. ESCRT-mediated membrane repair protects tumor-derived cells against T cell attack. Science. 2022;376(6591):377–82.
pubmed: 35446649
doi: 10.1126/science.abl3855
Liu J, Kang R, Tang D. ESCRT-III-mediated membrane repair in cell death and tumor resistance. Cancer Gene Ther. 2021;28(1–2):1–4.
pubmed: 32669618
doi: 10.1038/s41417-020-0200-0
Babst M, et al. Endosome-associated complex, ESCRT-II, recruits transport machinery for protein sorting at the multivesicular body. Dev Cell. 2002;3(2):283–9.
pubmed: 12194858
doi: 10.1016/S1534-5807(02)00219-8
Babst M, et al. Escrt-III: an endosome-associated heterooligomeric protein complex required for mvb sorting. Dev Cell. 2002;3(2):271–82.
pubmed: 12194857
doi: 10.1016/S1534-5807(02)00220-4
Schöneberg J, et al. Reverse-topology membrane scission by the ESCRT proteins. Nat Rev Mol Cell Biol. 2017;18(1):5–17.
pubmed: 27703243
doi: 10.1038/nrm.2016.121
Katzmann DJ, Babst M, Emr SD. Ubiquitin-dependent sorting into the multivesicular body pathway requires the function of a conserved endosomal protein sorting complex, ESCRT-I. Cell. 2001;106(2):145–55.
pubmed: 11511343
doi: 10.1016/S0092-8674(01)00434-2
Rühl S, et al. ESCRT-dependent membrane repair negatively regulates pyroptosis downstream of GSDMD activation. Science. 2018;362(6417):956–60.
pubmed: 30467171
doi: 10.1126/science.aar7607
Dai E, et al. ESCRT-III–dependent membrane repair blocks ferroptosis. Biochem Biophys Res Commun. 2020;522(2):415–21.
pubmed: 31761326
doi: 10.1016/j.bbrc.2019.11.110
Tang D, et al. PAMP s and DAMP s: signal 0s that spur autophagy and immunity. Immunol Rev. 2012;249(1):158–75.
pubmed: 22889221
pmcid: 3662247
doi: 10.1111/j.1600-065X.2012.01146.x
Gregor L, Stock S, Kobold S. ESCRT machinery: role of membrane repair mechanisms in escaping cell death. Signal Transduct Target Ther. 2022;7(1):238.
pubmed: 35842417
pmcid: 9288431
doi: 10.1038/s41392-022-01108-6
Sønder SL, et al. Annexin A7 is required for ESCRT III-mediated plasma membrane repair. Sci Rep. 2019;9(1):6726.
pubmed: 31040365
pmcid: 6491720
doi: 10.1038/s41598-019-43143-4
Sadler JB, et al. A cancer-associated polymorphism in ESCRT-III disrupts the abscission checkpoint and promotes genome instability. Proc Natl Acad Sci. 2018;115(38):E8900–8.
pubmed: 30181294
pmcid: 6156662
doi: 10.1073/pnas.1805504115
Yang Y, Wang M. Genomic analysis of the endosomal sorting required for transport complex III pathway genes as therapeutic and prognostic biomarkers for endometrial carcinoma. Transl Cancer Res. 2022;11(9):3108–27.
pubmed: 36237250
pmcid: 9552276
doi: 10.21037/tcr-22-660
Lee J, et al. Substrate degradation by the anaphase promoting complex occurs during mitotic slippage. Cell Cycle. 2010;9(9):1792–801.
pubmed: 20436289
doi: 10.4161/cc.9.9.11519
Maugeri-Saccà M, Vigneri P, De Maria R. Cancer stem cells and chemosensitivity. Clin Cancer Res. 2011;17(15):4942–7.
pubmed: 21622723
doi: 10.1158/1078-0432.CCR-10-2538
Lara-Gonzalez P, Westhorpe FG, Taylor SS. The spindle assembly checkpoint. Curr Biol. 2012;22(22):R966–80.
pubmed: 23174302
doi: 10.1016/j.cub.2012.10.006
Lok TM, et al. Mitotic slippage is determined by p31comet and the weakening of the spindle-assembly checkpoint. Oncogene. 2020;39(13):2819–34.
pubmed: 32029899
pmcid: 7098889
doi: 10.1038/s41388-020-1187-6
Nakayama Y, Inoue T. Antiproliferative fate of the tetraploid formed after mitotic slippage and its promotion; a novel target for cancer therapy based on microtubule poisons. Molecules. 2016;21(5):663.
pubmed: 27213315
pmcid: 6274067
doi: 10.3390/molecules21050663
Yu H. Structural activation of Mad2 in the mitotic spindle checkpoint: the two-state Mad2 model versus the Mad2 template model. J Cell Biol. 2006;173(2):153–7.
pubmed: 16636141
pmcid: 2063805
doi: 10.1083/jcb.200601172
Qiao X, et al. APC/C-Cdh1: from cell cycle to cellular differentiation and genomic integrity. Cell Cycle. 2010;9(19):3904–12.
pubmed: 20935501
pmcid: 3047751
doi: 10.4161/cc.9.19.13585
Park YY, et al. ATP depletion during mitotic arrest induces mitotic slippage and APC/CCdh1-dependent cyclin B1 degradation. Exp Mol Med. 2018;50(4):1–14.
pubmed: 30523262
pmcid: 6052162
doi: 10.1038/s12276-018-0069-2
Stevens FE, et al. Histone deacetylase inhibitors induce mitotic slippage. Oncogene. 2008;27(10):1345–54.
pubmed: 17828304
doi: 10.1038/sj.onc.1210779
Caydasi AK, et al. SWR1 chromatin remodeling complex prevents mitotic slippage during spindle position checkpoint arrest. Mol Biol Cell. 2023;34(2):ar11.
pubmed: 36542480
pmcid: 9930528
doi: 10.1091/mbc.E20-03-0179
Ruggiero A, et al. The phosphatase PP1 promotes mitotic slippage through Mad3 dephosphorylation. Curr Biol. 2020;30(2):335–43.
pubmed: 31928870
doi: 10.1016/j.cub.2019.11.054
Pavani M, et al. Triap1 upregulation promotes escape from mitotic-slippage-induced G1 arrest. Cell Rep. 2023;42(3): 112215.
pubmed: 36917609
doi: 10.1016/j.celrep.2023.112215
Cheng B, Crasta K. Consequences of mitotic slippage for antimicrotubule drug therapy. Endocr Relat Cancer. 2017;24(9):T97–106.
pubmed: 28684541
doi: 10.1530/ERC-17-0147
Zhu Y, Zhou Y, Shi J. Post-slippage multinucleation renders cytotoxic variation in anti-mitotic drugs that target the microtubules or mitotic spindle. Cell Cycle. 2014;13(11):1756–64.
pubmed: 24694730
pmcid: 4111722
doi: 10.4161/cc.28672
Jakhar R, et al. Autophagy governs protumorigenic effects of mitotic slippage–induced senescence. Mol Cancer Res. 2018;16(11):1625–40.
pubmed: 30037855
doi: 10.1158/1541-7786.MCR-18-0024
Suleimenov M, et al. Bcl-xL activity influences outcome of the mitotic arrest. Front Pharmacol. 2022;13: 933112.
pubmed: 36188556
pmcid: 9520339
doi: 10.3389/fphar.2022.933112
Matuszyk J, Klopotowska D. miR-125b lowers sensitivity to apoptosis following mitotic arrest: implications for breast cancer therapy. J Cell Physiol. 2020;235(10):6335–44.
pubmed: 32052874
doi: 10.1002/jcp.29610
Raj AT, et al. Potential role of anastasis in cancer initiation and progression. Apoptosis. 2019;24(5–6):383–4.
pubmed: 30937671
doi: 10.1007/s10495-019-01538-8
Mohammed RN, et al. Anastasis: cell recovery mechanisms and potential role in cancer. Cell Commun Signal. 2022;20(1):81.
pubmed: 35659306
pmcid: 9166643
doi: 10.1186/s12964-022-00880-w
Sun G, Montell DJ. Q&A: cellular near death experiences—What is anastasis? BMC Biol. 2017;15(1):1–5.
doi: 10.1186/s12915-017-0441-z
Tang HM, Tang HL. Anastasis: recovery from the brink of cell death. R Soc Open Sci. 2018;5(9): 180442.
pubmed: 30839720
pmcid: 6170572
doi: 10.1098/rsos.180442
Tang HL, et al. In vivo CaspaseTracker biosensor system for detecting anastasis and non-apoptotic caspase activity. Sci Rep. 2015;5(1):9015.
pubmed: 25757939
pmcid: 4355673
doi: 10.1038/srep09015
Tang HM, et al. Molecular signature of anastasis for reversal of apoptosis. F1000Research. 2017;6:43.
pubmed: 28299189
pmcid: 5310529
doi: 10.12688/f1000research.10568.1
Tang HM, et al. Transcriptomic study of anastasis for reversal of ethanol-induced apoptosis in mouse primary liver cells. Sci Data. 2022;9(1):418.
pubmed: 35851273
pmcid: 9293995
doi: 10.1038/s41597-022-01470-8
Tang HM, Fung MC, Tang HL. Detecting anastasis in vivo by CaspaseTracker biosensor. J Visualiz Exp. 2018;132: e54107.
Zakharov I, Savitskaya M, Onishchenko G. The problem of apoptotic processes reversibility. Biochem Mosc. 2020;85:1145–58.
doi: 10.1134/S000629792010003X
Xu Y, et al. Apoptosis reversal promotes cancer stem cell-like cell formation. Neoplasia. 2018;20(3):295–303.
pubmed: 29476980
pmcid: 5883632
doi: 10.1016/j.neo.2018.01.005
Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275–84.
pubmed: 15803154
doi: 10.1038/nrc1590
Golebiewska A, et al. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell. 2011;8(2):136–47.
pubmed: 21295271
doi: 10.1016/j.stem.2011.01.007
Klonisch T, et al. Cancer stem cell markers in common cancers–therapeutic implications. Trends Mol Med. 2008;14(10):450–60.
pubmed: 18775674
doi: 10.1016/j.molmed.2008.08.003
Pece S, et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell. 2010;140(1):62–73.
pubmed: 20074520
doi: 10.1016/j.cell.2009.12.007
Cho, R.W. and M.F. Clarke, Recent advances in cancer stem cells. Current Opinion in Genetics & d+Development. 2008;18(1):48–53.
Jinesh G, Kamat A. Blebbishield emergency program: an apoptotic route to cellular transformation. Cell Death Differ. 2016;23(5):757.
pubmed: 26967969
pmcid: 4832111
doi: 10.1038/cdd.2016.26
Jinesh G, et al. Blebbishields, the emergency program for cancer stem cells: sphere formation and tumorigenesis after apoptosis. Cell Death Differ. 2013;20(3):382–95.
pubmed: 23175184
doi: 10.1038/cdd.2012.140
Jinesh GG, Kamat AM. The blebbishield emergency program overrides chromosomal instability and phagocytosis checkpoints in cancer stem cells. Can Res. 2017;77(22):6144–56.
doi: 10.1158/0008-5472.CAN-17-0522
Mattila PK, Lappalainen P. Filopodia: molecular architecture and cellular functions. Nat Rev Mol Cell Biol. 2008;9(6):446–54.
pubmed: 18464790
doi: 10.1038/nrm2406
Silvera D, Formenti SC, Schneider RJ. Translational control in cancer. Nat Rev Cancer. 2010;10(4):254–66.
pubmed: 20332778
doi: 10.1038/nrc2824
Jinesh GG, Kamat AM. Blebbishields and mitotic cells exhibit robust macropinocytosis. BioFactors. 2017;43(2):181–6.
pubmed: 27671897
doi: 10.1002/biof.1335
Jinesh G, et al. Mitochondrial oligomers boost glycolysis in cancer stem cells to facilitate blebbishield-mediated transformation after apoptosis. Cell Death Discovery. 2016;2(1):1–12.
doi: 10.1038/cddiscovery.2016.3
Jinesh GG, Kamat AM. Endocytosis and serpentine filopodia drive blebbishield-mediated resurrection of apoptotic cancer stem cells. Cell Death Discovery. 2016;2(1):1–10.
doi: 10.1038/cddiscovery.2015.69
Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene. 2003;22(56):8999–9006.
pubmed: 14663478
doi: 10.1038/sj.onc.1207111
Danial N. BAD: undertaker by night, candyman by day. Oncogene. 2008;27(1):S53–70.
pubmed: 19641507
doi: 10.1038/onc.2009.44
Tang FH, et al. KRAS mutation coupled with p53 loss is sufficient to induce ovarian carcinosarcomas in mice. Int J Cancer. 2017;140(8):1860–9.
pubmed: 28032649
doi: 10.1002/ijc.30591
Jinesh GG, et al. Mutant p53s and chromosome 19 microRNA cluster overexpression regulate cancer testis antigen expression and cellular transformation in hepatocellular carcinoma. Sci Rep. 2021;11(1):12673.
pubmed: 34135394
pmcid: 8209049
doi: 10.1038/s41598-021-91924-7
Taoka R, et al. CF 3 DODA-Me induces apoptosis, degrades Sp1, and blocks the transformation phase of the blebbishield emergency program. Apoptosis. 2017;22:719–29.
pubmed: 28283889
doi: 10.1007/s10495-017-1359-1
Jinesh GG, Levi Willis D, Kamat AM. Bladder cancer stem cells: biological and therapeutic perspectives. Curr Stem Cell Res Ther. 2014;9(2):89–101.
doi: 10.2174/1574888X08666131113123051
Jinesh GG, et al. Novel PKC-ζ to p47phox interaction is necessary for transformation from blebbishields. Sci Rep. 2016;6(1):23965.
pubmed: 27040869
pmcid: 4819220
doi: 10.1038/srep23965
Milo GE, et al. Inhibition of carcinogen-induced cellular transformation of human fibroblasts by drugs that interact with the poly (ADP-ribose) polymerase system: Initial evidence for the development of transformation resistance. FEBS Lett. 1985;179(2):332–6.
pubmed: 2981708
doi: 10.1016/0014-5793(85)80546-9
Morozevich G, et al. Implication of α2β1 integrin in anoikis of MCF-7 human breast carcinoma cells. Biochem Mosc. 2015;80:97–103.
doi: 10.1134/S0006297915010113
Bianchi ME, Mezzapelle R. The chemokine receptor CXCR4 in cell proliferation and tissue regeneration. Front Immunol. 2020;11: 560971.
doi: 10.3389/fimmu.2020.02109
Kochetkova M, Kumar S, McColl S. Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells. Cell Death Differ. 2009;16(5):664–73.
pubmed: 19136936
doi: 10.1038/cdd.2008.190
Li Y, et al. VSTM2L contributes to anoikis resistance and acts as a novel biomarker for metastasis and clinical outcome in ovarian cancer. Biochem Biophys Res Commun. 2023;658:107–15.
pubmed: 37030064
doi: 10.1016/j.bbrc.2023.03.073
McGriff SC, et al. Optimal endocrine evaluation and treatment of male infertility. Urol Clin. 2020;47(2):139–46.
doi: 10.1016/j.ucl.2019.12.002
Assidi M. Infertility in men: advances towards a comprehensive and integrative strategy for precision theranostics. Cells. 2022;11(10):1711.
pubmed: 35626747
pmcid: 9139678
doi: 10.3390/cells11101711
Kiserud CE, et al. Gonadal function after cancer treatment in adult men. Tidsskrift for den Norske laegeforening: tidsskrift for praktisk medicin, ny raekke. 2008;128(4):461–5.
pubmed: 18274582
Bhasin S, Salehian B. Gonadotropin therapy of men with hypogonadotropic hypogonadism. Curr Ther Endocrinol Metab. 1997;6:349–52.
pubmed: 9174768
Brinton LA, Sahasrabuddhe VV and Scoccia B. Fertility drugs and the risk of breast and gynecologic cancers. In: Seminars in reproductive medicine. 2012. Thieme Medical Publishers.
Gasparri ML, et al. Biological impact of unilateral oophorectomy: does the number of ovaries really matter? Geburtshilfe Frauenheilkd. 2021;81(03):331–8.
pubmed: 33692594
doi: 10.1055/a-1239-3958
Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):748–58.
pubmed: 24688118
pmcid: 4326303
doi: 10.1093/humupd/dmu012
Fukazawa T, et al. Accelerated degradation of cellular FLIP protein through the ubiquitin-proteasome pathway in p53-mediated apoptosis of human cancer cells. Oncogene. 2001;20(37):5225–31.
pubmed: 11526513
doi: 10.1038/sj.onc.1204673
Borrelli S, et al. p63 regulates the caspase-8-FLIP apoptotic pathway in epidermis. Cell Death Differ. 2009;16(2):253–63.
pubmed: 18927586
doi: 10.1038/cdd.2008.147
Benoit V, et al. Caspase-8-dependent HER-2 cleavage in response to tumor necrosis factor α stimulation is counteracted by nuclear factor κB through c-FLIP-L expression. Can Res. 2004;64(8):2684–91.
doi: 10.1158/0008-5472.CAN-03-2914
Kreuz S, et al. NF-κB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol. 2001;21(12):3964–73.
pubmed: 11359904
pmcid: 87059
doi: 10.1128/MCB.21.12.3964-3973.2001
Micheau O, et al. NF-κB signals induce the expression of c-FLIP. Mol Cell Biol. 2001;21(16):5299–305.
pubmed: 11463813
pmcid: 87253
doi: 10.1128/MCB.21.16.5299-5305.2001
Lin Y, et al. Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. Mol Cancer Ther. 2008;7(11):3556–65.
pubmed: 19001438
doi: 10.1158/1535-7163.MCT-08-0648
Ricci MS, et al. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol Cell Biol. 2004;24(19):8541–55.
pubmed: 15367674
pmcid: 516765
doi: 10.1128/MCB.24.19.8541-8555.2004
Li W, Zhang X, Olumi AF. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP (L). Can Res. 2007;67(5):2247–55.
doi: 10.1158/0008-5472.CAN-06-3793
Zhang X, et al. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Can Res. 2007;67(19):9425–34.
doi: 10.1158/0008-5472.CAN-07-1310
Nam SY, et al. Upregulation of FLIPS by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci. 2003;94(12):1066–73.
pubmed: 14662022
pmcid: 11160312
doi: 10.1111/j.1349-7006.2003.tb01402.x
Skurk C, et al. The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J Biol Chem. 2004;279(2):1513–25.
pubmed: 14551207
doi: 10.1074/jbc.M304736200
Hsu T-S, et al. c-FLIP is a target of the E3 ligase deltex1 in gastric cancer. Cell Death Dis. 2018;9(2):135.
pubmed: 29374180
pmcid: 5833402
doi: 10.1038/s41419-017-0165-6
Schäfer JA, et al. ESCRT machinery mediates selective microautophagy of endoplasmic reticulum in yeast. EMBO J. 2020;39(2): e102586.
pubmed: 31802527
doi: 10.15252/embj.2019102586
Strack B, et al. AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell. 2003;114(6):689–99.
pubmed: 14505569
doi: 10.1016/S0092-8674(03)00653-6
Chittenden B, et al. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online. 2009;19(3):398–405.
pubmed: 19778486
doi: 10.1016/S1472-6483(10)60175-7
Concepción-Zavaleta MJ, et al. Thyroid disfunction and female infertility. A comprehensive review. Diabet Metab Syndrome. 2023;17(11): 102876.
doi: 10.1016/j.dsx.2023.102876
Jiang YT, et al. Infertility and ovarian cancer risk: Evidence from nine prospective cohort studies. Int J Cancer. 2020;147(8):2121–30.
pubmed: 32285933
doi: 10.1002/ijc.33012
Tang HM, et al. Molecular signature of anastasis for reversal of apoptosis. F1000Res. 2017;6:43.
pubmed: 28299189
pmcid: 5310529
doi: 10.12688/f1000research.10568.1
Seervi M, et al. Molecular profiling of anastatic cancer cells: potential role of the nuclear export pathway. Cell Oncol (Dordr). 2019;42(5):645–61.
pubmed: 31147963
doi: 10.1007/s13402-019-00451-1